Zymeworks leadership appointments and transitions to align with corporate strategy

Zymeworks announced appointments, promotions, retirements and reductions to its leadership team intended to align roles with the company’s corporate strategy announced in November; the firm named Brian Cherry to its Board and said Dr. Sabeen Mekan will transition to Chief Medical Officer effective February 1, 2026.

Zymeworks Inc. announced changes to its senior leadership on Jan. 12, 2026. The Vancouver-based biotechnology company said the updates include appointments, promotions, retirements and reductions. The company described the changes as intended to strengthen organizational capability. The firm also said the moves align with its corporate strategy announced in November. Notable leadership updates: - Investment industry veteran Mr. Brian Cherry appointed to the Board of Directors. - Dr. Sabeen Mekan will transition to Chief Medical Officer effective February 1, 2026. - Mark Hollywood promoted to Executive Vice President and Chief Operating Officer. - Five new Vice Presidents appointed to the leadership team. - The announcement also referenced retirements and reductions among other leadership positions. Summary: The company presents these changes as part of a planned realignment to support its portfolio of licensed healthcare assets and ongoing biotherapeutics development. The CMO transition has a stated effective date of February 1, 2026; broader timelines for other changes are undetermined at this time.